Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 7/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.53 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.53 |
| ▸ | FPR2 | P25090 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4603389 | 1.00 | CA2 (0.53) | CA2CA1CXCR2CXCR1CX3CR1 | |
| SCHEMBL4603663 | 0.89 | POLB (0.53) | CA2CA1CXCR2CXCR1CX3CR1 | |
| SCHEMBL4603360 | 0.85 | CXCR2 (0.58) | CA2CA1CXCR2CXCR1CX3CR1 | |
| SCHEMBL4604026 | 0.84 | CXCR2 (0.59) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL4604802 | 0.82 | CXCR2 (0.63) | CA2CA1CXCR2CXCR1CX3CR1 | |
| SCHEMBL4604688 | 0.81 | CXCR2 (0.56) | CA2CA1CXCR2CXCR1CX3CR1 | |
| Isoleucine SCHEMBL27573325 | 0.80 | CXCR2 (0.50) | CA2CA1CXCR2CXCR1CX3CR1 | |
| SCHEMBL4607210 | 0.78 | CXCR2 (0.63) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL4605221 | 0.76 | CXCR2 (0.60) | CA2CA1CXCR2CXCR1CX3CR1 | |
| SCHEMBL6444067 | 0.75 | CXCR2 (0.54) | CA2CA1CXCR2CXCR1CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265603-B1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-16 | — | — | EP | claimed |
| EP-1265603-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-09-28 | — | — | EP | claimed |
| US-6767922-B2 | ADMINISTERING N-(3-AMINOSULFONYL-2-HYDROXYPHENYL)-UREA DERIVATIVES; TREATMENT OF RESPIRATORY AND NERVOUS SYSTEM DISORDERS; ARTHRITIS, ASTHMA; VIRICIDES | SMITHKLINE BEECHAM CORPORATION | 2004-07-27 | — | — | US | claimed |
| US-20030065188-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | claimed |
| EP-1265603-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001068570-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-20 | — | — | WO | claimed |
| EP-1265603-B1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1265603-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-09-28 | — | — | EP | disclosed |
| US-6767922-B2 | ADMINISTERING N-(3-AMINOSULFONYL-2-HYDROXYPHENYL)-UREA DERIVATIVES; TREATMENT OF RESPIRATORY AND NERVOUS SYSTEM DISORDERS; ARTHRITIS, ASTHMA; VIRICIDES | SMITHKLINE BEECHAM CORPORATION | 2004-07-27 | — | — | US | disclosed |
| US-20030065188-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | disclosed |
| EP-1265603-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001068570-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065188-A1 | Il-8 receptor antagonists | CXCL8, CCR8, IL1RN | CA2 3402/4885CA1 3382/4885CXCR2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.